EP0866799A4 - Apolipoproteine e2 et traitement de la maladie d'alzheimer - Google Patents

Apolipoproteine e2 et traitement de la maladie d'alzheimer

Info

Publication number
EP0866799A4
EP0866799A4 EP96937887A EP96937887A EP0866799A4 EP 0866799 A4 EP0866799 A4 EP 0866799A4 EP 96937887 A EP96937887 A EP 96937887A EP 96937887 A EP96937887 A EP 96937887A EP 0866799 A4 EP0866799 A4 EP 0866799A4
Authority
EP
European Patent Office
Prior art keywords
apolipoprotein
alzheimer
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96937887A
Other languages
German (de)
English (en)
Other versions
EP0866799A1 (fr
Inventor
Vassilis I Zannis
Sergie B Aleshkov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Kos Pharmaceuticals Inc
Original Assignee
Boston University
Kos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University, Kos Pharmaceuticals Inc filed Critical Boston University
Publication of EP0866799A1 publication Critical patent/EP0866799A1/fr
Publication of EP0866799A4 publication Critical patent/EP0866799A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP96937887A 1995-11-01 1996-10-31 Apolipoproteine e2 et traitement de la maladie d'alzheimer Withdrawn EP0866799A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55172295A 1995-11-01 1995-11-01
US551722 1995-11-01
PCT/US1996/017629 WO1997016458A1 (fr) 1995-11-01 1996-10-31 Apolipoproteine e2 et traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
EP0866799A1 EP0866799A1 (fr) 1998-09-30
EP0866799A4 true EP0866799A4 (fr) 2000-08-23

Family

ID=24202413

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96937887A Withdrawn EP0866799A4 (fr) 1995-11-01 1996-10-31 Apolipoproteine e2 et traitement de la maladie d'alzheimer

Country Status (7)

Country Link
EP (1) EP0866799A4 (fr)
JP (1) JP2000500332A (fr)
AU (1) AU720446B2 (fr)
BR (1) BR9611329A (fr)
CA (1) CA2236274A1 (fr)
MX (1) MX9803422A (fr)
WO (1) WO1997016458A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121429A2 (fr) * 1998-10-16 2001-08-08 Introgene B.V. Therapie genique de la maladie d'alzheimer par administration d'une apolipoproteine e codee
JP2002530122A (ja) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
CN1315402A (zh) * 2000-03-28 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白14和编码这种多肽的多核苷酸
CN1315439A (zh) * 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白9和编码这种多肽的多核苷酸
US20070036761A1 (en) * 2003-09-26 2007-02-15 Bales Kelly R Lentiviral apoe2 gene therapy
EP1991252A2 (fr) * 2006-02-21 2008-11-19 Oklahoma Medical Research Foundation Traitement de la maladie d'alzheimer avec des inhibiteurs de la fixation de l'apoe au récepteur de l'apoe
WO2010020822A1 (fr) * 2008-08-19 2010-02-25 University Of Patras Thérapie d’hypertriglycéridémie induite par apolipoprotéine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002670A1 (fr) * 1994-07-20 1996-02-01 Smithkline Beecham Plc PROCEDE POUR PRONOSTIQUER L'EVOLUTION ET LE DEGRE DE LA DEMENCE CHEZ DES PATIENTS ATTEINTS DE β-AMYLOSES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002670A1 (fr) * 1994-07-20 1996-02-01 Smithkline Beecham Plc PROCEDE POUR PRONOSTIQUER L'EVOLUTION ET LE DEGRE DE LA DEMENCE CHEZ DES PATIENTS ATTEINTS DE β-AMYLOSES

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 1994, 1994, Philadelphia, PA, US; abstract no. 345993, E H CORDER ET AL.: "Protective effect of apolioprotein E type 2 allele for late onset Alzheimer disease" XP002140639 *
C S HANLON & D C RUBINSZTEIN: "Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the ancestral state in humans.", ATHEROSCLEROSIS, vol. 112, no. 1, 6 January 1995 (1995-01-06), AMSTERDAM, NL, pages 85 - 90, XP002005036, ISSN: 0021-9150, DOI: doi:10.1016/0021-9150(94)05402-5 *
C TALBOT ET AL.: "Protection against Alzheimer's disease with apoE epsilon 2", LANCET THE., vol. 343, 4 June 1994 (1994-06-04), LANCET LIMITED. LONDON., GB, pages 1432 - 1433, XP002140637, ISSN: 0140-6736 *
File Medline, abstract 95290021, 1995 *
NATURE GENETICS., vol. 7, no. 2, 1994, pages 180 - 184, ISSN: 1061-4036 *
See also references of WO9716458A1 *

Also Published As

Publication number Publication date
WO1997016458A1 (fr) 1997-05-09
MX9803422A (es) 1998-11-29
EP0866799A1 (fr) 1998-09-30
CA2236274A1 (fr) 1997-05-09
AU7552696A (en) 1997-05-22
AU720446B2 (en) 2000-06-01
JP2000500332A (ja) 2000-01-18
BR9611329A (pt) 1999-12-28

Similar Documents

Publication Publication Date Title
AU2830097A (en) Therapeutic method for treatment of alzheimer's disease
ZA9410095B (en) Methods of inhibiting Alzheimer's Disease
AU7397094A (en) Prevention and treatment of alzheimer's disease
EP0735870A4 (fr) Utilisation d'inhibiteurs de pla 2? pour traiter la maladie d'alzheimer
AU4650096A (en) Neural thread protein gene expression and detection of alzheimer's disease
HU9302551D0 (en) Compounds having effect against hypoglycemia and alzheimer's disease
EP1043991A4 (fr) Traitement contre la maladie d'alzheimer
EP0746322A4 (fr) Traitement de la maladie d'alzheimer et modulation du systeme immunitaire a l'aide de delta5-androstenes
GB9316727D0 (en) Models of alzheimers's disease
IL105216A0 (en) Method and kit for the diagnosis of alzheimer's disease
AU3279395A (en) Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
ZA962846B (en) Treatment of traveller's diarrhea
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
EP0866799A4 (fr) Apolipoproteine e2 et traitement de la maladie d'alzheimer
EP0842189A4 (fr) Gene et produits geniques de la maladie d'alzheimer precoce
GB9602162D0 (en) Treatment of waste
EP0833641A4 (fr) Traitement et prevention de maladies prostatiques
EP0862442A4 (fr) Procede permettant de diagnostiquer et de traiter le syndrome de bloom
GB9516572D0 (en) Prevention and/or treatment of disease
GB9709416D0 (en) Methods for treatment of alzheimer's disease using azaspiranes
GB9323826D0 (en) Diagnosis of alzheimer's disease
ZA961060B (en) Treatment of titanium-containing material
GB9517266D0 (en) Diagnosis of alzheimer's disease
AU8700998A (en) Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000706

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010621

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020903